Sanofi, UCB team up to develop drugs for inflammatory diseases

Sanofi (SNY) is partnering with Belgium's UCB to develop anti-inflammatory small molecules that could be used "to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis."

Sanofi will make upfront and milestone payments that have the potential to surpass €100M.

The companies will share costs and profits on a 50-50 basis.

The agreement is the latest example of a major pharmaceutical company looking externally for new drugs. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs